Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
SEOUL, South Korea, March 23, 2023 /PRNewswire/ -- CodeSteri, a leading provider of disinfection solutions, is proud to announce the launch of PlaClin-M, a revolutionary device designed to help ensure a clean and safe environment in offices, commercial establishments, and public spaces. CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and...
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, March 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosing of first patient in the U.S. Phase I Study of TST003 (NCT05731271), its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, for the treatment of...
Transcenta to Present Two Preclinical Studies at AACR 2023
SUZHOU, China, March 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that two preclinical studies in relation to TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb will be presented as posters at the...
Aquavit Awarded 10M in Damages on Intellectual Property Against Counterfeiters
NEW YORK, March 23, 2023 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") today received a final award in the amount of $10,088,380.72 from the United States District Court for the Southern District of New York. The Honorable Valerie Caproni adopted the Report & Recommendation (R&R) of the Honorable Robert W. Lehrburger in full,...
Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma
SUZHOU, China and ROCKVILLE, Md., March 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During the reporting period, the company upheld the concept of original...
Jacobio Pharma Announces 2022 Annual Results
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment was RMB530 million, showing an increase of 26% compared with 2021. The revenue was RMB95.7 million, which was generated from an out-licensing deal. Jacobio Pharma also announced its recent business progress and expected milestones. Dr. Wang...
Daewoong Pharmaceutical’s Envlo to enter the global market in full swing with filing for product license in three ASEAN countries
Submitted an NDA to Indonesia, Philippines and Thailand Signed the export contract in Brazil and Mexico in last February Aiming to enter 50 countries by 2030 SEOUL, South Korea, March 22, 2023 /PRNewswire/ -- Daewoong Pharmaceutical began the advance into the global market in full swing with their national...
Jolly Good and Harvard University Hospital collaborate on medical VR – Full-scale entry into the U.S. market
~ Dr. Kei Ouchi, Associate Professor of Medicine at Harvard Medical School, appointed as Jolly Good Medical Advisor ~ TOKYO, March 22, 2023 /PRNewswire/ -- (Chuo-ku, Tokyo; President: Kensuke Joji; hereinafter "Jolly Good"), in collaboration with Brigham and Women's Hospital (Boston, Massachusetts, USA; Director: Sunil Eappen; hereinafter "BWH"), a hospital affiliated with Harvard University, develops emergency care VR content....
CARsgen Announced 2022 Annual Results and Business Updates
SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results. Business Highlights Zevor-cel (CT053) NDA was accepted by the NMPA (Oct 2022) with priority review granted....
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19, 2023. BSI-507, a First-in-Class Bispecific...
